$CELC News

Will Breast And Prostate Cancer Data Change Celcuity (CELC) Narrative

Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026

Celcuity Presents Updated Data from a Phase 1b/2 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration-Resistant Prostate Cancer at the ESMO Congress 2026

Cantor sees ‘credible path to multi-billion-dollar peak sales’ for Celcuity

Cantor Fitzgerald Initiates Coverage On Celcuity with Overweight Rating, Announces Price Target of $140

TD Cowen Reiterates Buy on Celcuity, Announces $145 Price Target

Celcuity (CELC) Stock May Be Hard To Value On Book Value

Celcuity (CELC) Is Down 17.3% After REVTORPYK US Launch And sNDA Filing News Event

Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026

Celcuity (CELC) Dropped, So What Is Behind Its Latest Move?

Celcuity Appoints David Gryska To Its Board Of Directors

Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States

Needham Maintains Buy on Celcuity, Lowers Price Target to $134

Celcuity Announces Commercial Availability Of REVTORPYK In U.S. For People With Hormone Receptor-Positive

Is Celcuity (CELC) Stock a Buy?

JP Morgan Initiates Coverage On Celcuity with Overweight Rating, Announces Price Target of $157

Celcuity Inc. (CELC) Presents at Citigroup's Biopharma Back to School Summit 2026 Prepared Remarks Transcript

Celcuity To Participate in Upcoming Investor Conferences

Celcuity (CELC): Landmark Approval Collides With A Costly Launch

Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer